SCHEMBL3093289

SCHEMBL3093289

CCN(CC)C(=O)C(Cc1ccc(NC(=O)c2cccc(N)c2)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 3/20 0.49
F2 P00734 2/20 0.43
LARS1 Q9P2J5 1/20 0.43
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
POLB P06746 1/20 0.41
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
GPR27 Q9NS67 1/20 0.41
AR P10275 1/20 0.41
PLG P00747 1/20 0.41
MEN1 O00255 5/20 0.41
KMT2A Q03164 5/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
LMNA P02545 1/20 0.39
TSHR P16473 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NR1H4 Q96RI1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3093732 0.92 LARS1 (0.44) F2LARS1NPC1RAB9AGPR27
SCHEMBL3093901 0.92 MMP9 (0.46) KAT6AF2LARS1NPC1RAB9A
SCHEMBL3102970 0.92 MMP9 (0.46) KAT6AF2LARS1NPC1RAB9A
SCHEMBL3092720 0.91 MEN1 (0.53) KAT6AF2LARS1NPC1RAB9A
SCHEMBL3085893 0.90 NPC1 (0.52) KAT6AF2LARS1NPC1RAB9A
SCHEMBL3097645 0.90 KAT6A (0.49) KAT6AF2LARS1NPC1RAB9A
SCHEMBL3096373 0.90 NPC1 (0.52) KAT6AF2LARS1NPC1RAB9A
SCHEMBL3080048 0.89 MEN1 (0.54) KAT6ANPC1RAB9APOLBCASP3
SCHEMBL3092605 0.88 KMT2A (0.55) NPC1RAB9APOLBMEN1KMT2A
SCHEMBL3103861 0.88 KAT6A (0.52) KAT6AF2NPC1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 KAT6A 3337/4885F2 4128/4885LARS1 1976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.